Daybue Q2 2024 revenue was $84.6M and represented a recent uncomplicated quarter results.Daybue Q1 2025 results of around $88.0M[in my view] suggests that Acadia has been virtually unable to improve revenue via increased patient numbers or better patient retention/fewer discontinuation numbers etc in the past six months as a buffer against the anticipated Q1 2025 pullback.I would have thought that the new CEO general initiatives and increasing penetration rates should have resulted in improved bottle sales over the last quarter sufficient to cover any potential Q4 2024 sales shortfall.
Kens
- Forums
- ASX - By Stock
- Acadia
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.54%
!
$12.92

Daybue Q2 2024 revenue was $84.6M and represented a recent...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.92 |
Change
0.070(0.54%) |
Mkt cap ! $1.607B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.85 | $8.049M | 616.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4175 | $12.91 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.03 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4175 | 12.910 |
4 | 4488 | 12.900 |
2 | 1762 | 12.890 |
2 | 3348 | 12.880 |
1 | 1508 | 12.850 |
Price($) | Vol. | No. |
---|---|---|
13.030 | 100 | 1 |
13.040 | 6060 | 2 |
13.050 | 1508 | 1 |
13.060 | 7205 | 8 |
13.080 | 1508 | 1 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online